Aktienanalyse zu Quantum Biopharma Ltd (QNTM)QNTMQuantum Biopharma Ltd

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. It operates in the Healthcare sector.

Quantum BioPharma Ltd (QNTM) is not a good buy right now due to its significant financial losses and declining stock performance. The current price is $2.09, which is 75.09% lower than its 1-year high of $12.42. The company has a negative gross profit of -129298 USD for Q1 2025 and a forward P/E of 0, indicating no expected earnings growth. Additionally, the RSI is at a very low 20.861, suggesting oversold conditions but also a lack of upward momentum. The main risk is the 70.19% year-to-date decline, which indicates ongoing challenges in the company's financial health and market perception.